Opinion

Video

Influence of Driver Mutations on Response to Ropeginterferon Alpha-2b in Patients with PV

Author(s):

John Mascarenhas, MD,Joe Scandura, MD, PhD

Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.

Related Videos
Michael R. Grunwald, MD, FACP
2 KOLs are featured in this series.
Daniel DeAngelo, MD, PhD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Acute Myeloid Leukemia
November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Fotograf – stock.adobe.com
November 13th 2024

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS

Courtney D. DiNardo, MD, MSCE
November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.
November 5th 2024

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute
October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis